Contract
Exhibit 10.8(g)
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Contract Amendment No. 6
to the
Development and Supply Agreement as of May 29, 2008
by and between
ViewRay Incorporated
with its registered seat in Xxxxxxx Xxxxxxx, XX, XXX
- hereinafter referred to as “VIEWRAY OR BUYER” -
And
Siemens AG
Healthcare Sector
- hereinafter referred to as “SIEMENS OR SELLER” -
- VIEWRAY and SIEMENS hereinafter referred to individually
as “Party” or collectively as “Parties” -
Preamble
The Parties have signed a Development and Supply Agreement on May 29, 2008, as amended (the “2008 Agreement”) with the intention to collaborate in the development of [***]. According to Appendix 2 of the 2008 Agreement as amended (the “SUPPLY AGREEMENT”) SIEMENS delivers certain components as described in Annex 1 to the SUPPLY AGREEMENT (“COMPONENTS”) to VIEWRAY for integration in their MRgRT systems With this Contract Amendment No. 6, the Parties agree (i) to the delivery of the COMPONENTS for the integration by VIEWRAY in the [***] and (ii) to the provision of limited fee-for-service technical assistance from SIEMENS to VIEWRAY with respect to VIEWRAY efforts [***]. For the avoidance of doubt, the activities contemplated by this Contract Amendment No. 6 are in addition to the activities of the Parties with respect to the supply of COMPONENTS by SIEMENS to VIEWRAY of MRI subsystems for MRgRT systems contemplated by the 2008 Agreement.
Agreement
Article 1. COMPONENTS and services for [***]
This Article 1 shall apply to COMPONENTS delivered for [***] but not for COMPONENTS delivered for MRgRT systems, which will continue to be governed by Section 2 of the SUPPLY AGREEMENT.
1.1 | VIEWRAY shall furnish to SIEMENS a forecast indicating its demand of COMPONENTS for the period of the next [***] following signature of this Contract |
Amendment No. 6. If SIEMENS does not object the forecast in writing within [***] after receipt of the forecast the forecast will be accepted by SIEMENS and SIEMENS will consider the forecast when planning its production capacities. In this case VIEWRAY may assume that SIEMENS will accept purchase orders within this scope. VIEWRAY shall place its orders in writing to SIEMENS and SIEMENS shall acknowledge these orders within [***] after receipt thereof, as far as they do not exceed the forecast accepted by SIEMENS. Section 2.3-2.6 of the Supply Agreement, as well as Articles 2 to 16 of the SUPPLY AGREEMENT shall apply respectively to the delivery of COMPONENTS unless otherwise agreed in this Contract Amendment No. 6. |
1.2 | SIEMENS will consider reasonable requests for technical assistance services from VIEWRAY concerning COMPONENTS for the [***]. If VIEWRAY requests such technical assistance services and SIEMENS agrees to provide such technical assistance services itself, or through its wholly-owned indirect U.S. subsidiary, Siemens Medical Solutions USA, Inc., then VIEWRAY shall pay for such technical assistance services at the rates established at the commencement of each request for services pursuant to this Article 1.2. VIEWRAY shall [***]. For the avoidance of doubt, SIEMENS shall not be obligated to agree to the provision of technical assistance services. The provision of technical assistance services shall be subject to the terms and conditions of SIEMENS for the provision of services applicable at the commencement of such technical assistance services. |
Article 2. Deviations from the SUPPLY AGREEMENT
This Article 2 shall apply to COMPONENTS delivered for MRgRT systems as well as to COMPONENTS delivered for [***].
Article 10 of the SUPPLY AGREEMENT shall be deleted and replaced as follows:
“10.1 | BUYER shall be responsible for its use of COMPONENTS and shall verify whether such use infringes any third party patent, utility models or copyright (hereinafter “Protective Rights”). |
10.2 | If a third party raises claims [***] its MRgRT systems or [***] (including but not limited to inducement to infringement and/or contributory infringement), [***] in the MRgRT systems or [***]. |
10.3 | SELLER does not assume any liability with regard to the MRgRT systems and/or [***] developed and/or sold by BUYER. Section 10.2 shall apply likewise in case a third party raises claims against SELLER for personal injury, damages to property, loss of business or revenue and/or any other damages caused by the use of the MRgRT systems and/or [***]. |
10.4 | [***] |
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Article 3. Export Control
This Article 3 shall apply to COMPONENTS delivered for MRgRT systems as well as to COMPONENTS delivered for [***].
3.1 | If VIEWRAY transfers COMPONENTS delivered by SIEMENS or technical assistance services performed by SIEMENS or its wholly-owned indirect U.S. subsidiary, Siemens Medical Solutions USA, Inc. to a third party VIEWRAY shall comply with all applicable national and international (re-) export control regulations. In any event of such transfer of COMPONENTS and/or technical assistance services VIEWRAY shall comply with the (re-) export control regulations of the Federal Republic of Germany, of the European Union and of the United States of America. |
3.2 | Prior to any transfer of COMPONENTS and/or technical assistance services provided by SIEMENS or its wholly-owned indirect U.S. subsidiary, Siemens Medical Solutions USA, Inc. to a third party VIEWRAY shall in particular check and guarantee by appropriate measures that there will be no infringement of an embargo imposed by the European Union, by the United States of America and/or by the United Nations by such transfer, by brokering of contracts concerning those goods, works and services or by provision of other economic resources in connection with those COMPONENTS and or and/or technical assistance services, also considering the limitations of domestic business and prohibitions of by-passing those embargos; |
3.3 | Such COMPONENTS and/or technical assistance services are not intended for use in connection with armaments, nuclear technology or weapons, if and to the extent such use is subject to prohibition or authorization, unless required authorization is provided; The regulations of all applicable Sanctioned Party Lists of the European Union and the United States of America concerning the trading with entities, persons and organizations listed therein are considered. |
3.4 | If required to enable authorities or SIEMENS or its wholly-owned indirect U.S. subsidiary, Siemens Medical Solutions USA, Inc. to conduct export control checks, VIEWRAY, upon request by SIEMENS, shall promptly provide SIEMENS with all information pertaining to the particular end customer, the particular destination and the particular intended use of goods, works and services provided by SIEMENS, as well as any export control restrictions existing. |
3.5 | VIEWRAY shall [***]. |
Article 4. Safety
This Article 4 shall apply to COMPONENTS delivered for MRgRT systems as well as for COMPONENTS delivered for [***].
4.1 | The Parties shall, also beyond the term of the SUPPLY AGREEMENT, collaborate to the best of their abilities in order to prevent identified or unidentified risks or damages as quickly and effectively as possible which may be caused by the COMPONENTS so that no one suffers any damage or injury as a result of using the COMPONENTS. |
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
4.2 | VIEWRAY shall be obliged to monitor the COMPONENTS used together with its own equipment or systems with regard to product defects of all kinds. The aforesaid obligation shall be carried out by VIEWRAY by appropriate organizational measures within the scope of its organizational and operational structure. VIEWRAY shall promptly notify SIEMENS in writing of any identified product defects in accordance with its quality assurance policies and procedures, provided that such policies and procedures are reasonably acceptable to SELLER. |
Article 5. Duration
This Contract Amendment No. 6 shall take effect on the date it is signed by both Parties and shall be valid until the SUPPLY AGREEMENT is terminated. Each Party’s right to terminate the SUPPLY AGREEMENT and/or this Contract Amendment No. 6 for good cause, including but not limited to the termination rights under 13.1(b) of the SUPPLY AGREEMENT, shall remain unaffected.
Article 6. Miscellaneous
6.1 | Except to the extent expressly amended by this Contract Amendment No. 6, all of the clauses and conditions of the 2008 Agreement shall remain unaffected. The term “Agreement”, as used in the 2008 Agreement, shall henceforth be deemed to be a reference to the 2008 Agreement as amended by this Contract Amendment No. 6. |
6.2 | This Contract Amendment No. 6 may be executed in counterparts, each of which will be deemed an original with all such counterparts together constituting one instrument. Capitalized terms used in this Contract Amendment No. 6 and not defined herein are used with the meanings ascribed to them in the 2008 Agreement. |
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
ViewRay Incorporated | ||||||||||
Place, Date: | ||||||||||
Mtn View, CA 15 Jan, 2014 |
||||||||||
/s/ Xxxxx Xxxxxx |
||||||||||
Name: | Xxxxx Xxxxxx |
|||||||||
(Print) | ||||||||||
Title: | Chief Executive Officer |
|||||||||
Siemens AG. | ||||||||||
Healthcare Sector | ||||||||||
Place, Date: | ||||||||||
Xxxxxxxx, 00.00.0000 |
Xxxxxxxx, 21.02.2014 |
|||||||||
i.V. /s/ Xxxxxxx Xxxxxx |
xX. /s/ Xxxxxx Xxxxxx |
|||||||||
Name: | Name: | |||||||||
Xxxxxxx Xxxxxx |
Xxxxxx Xxxxxx |
|||||||||
(Print) | (Print) | |||||||||
Title: | Head of H/M MRTR |
Title: | CFO Magnetic Resonance |
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.